Innovent Biologics (HKG:1801) recorded a total product revenue of over 2.4 billion yuan in the first quarter, up 40% from a year prior, a Thursday Hong Kong bourse filing said.
The drugmaker launched four new products in the quarter, comprising Dovbleron, Limertinib, and Jaypirca in the oncology niche, and SYCUME in the field of general biomedicine.
To date, the company has 15 approved products, three new drug applications under regulatory review, four assets in phase III or pivotal clinical trials, and 15 more molecules in early clinical stage.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。